In observance of the Independence Day holiday, U.S. stock markets and SogoTrade will be closed on Monday, July 4, 2022
   Cryptocurrency trading will continue as usual, around the clock, throughout the holiday weekend. 

Imagine you want to buy 1000 shares of the GERM ETF that is trading $33.00 bid and $33.02 ask. To enter a qualifying limit order and Get Paid to Trade*, you would simply enter an order to buy 1000 shares of GERM at $33.01 or lower. Upon execution, you will receive 1000 shares GERM at $0 commission and a credit to your account of $3. That’s it.

* Get Paid to Trade is a promotion offered exclusively by SogoTrade, Inc.

SogoTrade provides two methods for entering qualifying limit orders in its trading platform.
• Traditional: Simply enter a limit order using the standard trading tools most of our customers are familiar with. If the order executes as illustrated in the example above, you get paid to trade.
• Get Paid to Trade Limit: SogoTrade makes it easier for customers to enter qualifying limit orders by also offering a limit order type that helps ensure the customer gets paid to trade.





ABOUT GERM

GERM is an Exchange-Traded Fund (ETF) designed to give exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. This ETF is focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies, and testing technologies.



  • • From Jan. 2011 to Jan. 2018 there were 36 epidemic events in the U.S. alone. 1
  • • New reports indicate the value of the global human vaccines market is expected to grow to $72.5 billion by 2024, representing a CAGR of 11.2% from 2016 to 2024. 2
  • • There are 20 combined pandemics and epidemics affecting the world today. 3
  • • Variations of coronavirus have been medically documented in approximately 9 instances since 1965. 4

Start Trading

GERM




HERE.

ABOUT THE FUND

ETFMG Treatments, Testing and Advancements ETF (GERM) holds US-listed companies engaged in and at the forefront of R&D, vaccines, therapies, and testing technologies.


The Fund’s investment objective seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.


Carefully consider the Fund’s investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund’s prospectus, which may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477), or by visiting www.etfmg.com/GERM. Read the prospectus carefully before investing.

  1. World Health Organization, “Managing Epidemics”, page 22: https://www.who.int/emergencies/diseases/managing-epidemics-interactive.pdf
  2. Vaccines and Vaccination conference series, Transparency Market Research, June 2020, Market analysis: https://europe.vaccineconferences.com
  3. World Health Organization: https://www.who.int/emergencies/diseases/en/
  4. “The Scientist”: A Brief History of Human Coronavirus 6/2/2020: https://www.the-scientist.com/news-opinion/a-brief-history-of-human-coronaviruses-67600

Investing involves risk, including loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Narrowly focused investments typically exhibit higher volatility. Treatment Companies and Testing Companies are involved in discovering, developing and commercializing novel drugs or tests with significant market potential. These companies face challenges including pre-clinical testing and clinical trial stages of development. Clinical trials may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than anticipated. Such companies may be dependent on their ability to secure significant funding for research, development, and commercialization of therapeutics, vaccines, tests, and other health care products or services. If there are delays in obtaining required regulatory and marketing approvals for products, the ability of such companies to generate revenue may be materially impaired. If regulatory approval is obtained, products will still remain subject to regulatory scrutiny with regulatory authorities having the ability to impose significant restrictions on the indicated uses or marketing. Lastly, even if a licensed product is achieved, such companies may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.

The Fund is a recently organized, non-diversified management investment company with limited operating history.

ETF Managers Group LLC is the investment adviser to the Fund.

The Fund is distributed by ETFMG Financial LLC. ETF Managers Group LLC and ETFMG Financial LLC are wholly owned subsidiaries of Exchange Traded Managers Group LLC (collectively, “ETFMG”). ETFMG is not affiliated with Prime Indexes or SogoTrade, Inc.